| __timestamp | ADMA Biologics, Inc. | Amicus Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 20717000 |
| Thursday, January 1, 2015 | 6745968 | 47269000 |
| Friday, January 1, 2016 | 8494742 | 71151000 |
| Sunday, January 1, 2017 | 18092835 | 88671000 |
| Monday, January 1, 2018 | 22502922 | 127200000 |
| Tuesday, January 1, 2019 | 25910757 | 169861000 |
| Wednesday, January 1, 2020 | 35050817 | 156407000 |
| Friday, January 1, 2021 | 42896889 | 192710000 |
| Saturday, January 1, 2022 | 52458024 | 213041000 |
| Sunday, January 1, 2023 | 59020000 | 275270000 |
Infusing magic into the data realm
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, ADMA Biologics, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting approaches in their SG&A expenditures. From 2014 to 2023, ADMA Biologics saw a steady increase in SG&A expenses, growing by over 1,100%, reflecting their aggressive expansion and operational scaling. In contrast, Amicus Therapeutics, with a more substantial initial outlay, increased their SG&A spending by approximately 1,230%, indicating a robust commitment to market penetration and administrative efficiency. By 2023, Amicus's SG&A expenses were nearly five times that of ADMA, highlighting their larger market footprint. This comparison underscores the diverse strategies employed by biotech firms in managing operational costs to drive growth and innovation.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Novartis AG and ADMA Biologics, Inc.
Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.